吉奥资讯: 著名的核酸蛋白质纯化产品制造商加拿大Norgen Biotek（吉奥的合作伙伴）今天宣布和丹麦Exiqon A/S签订协议，前者将向后者，以OEM的方式提供拥有专利技术的RNA提取试剂盒。丹麦Exiqon公司在microRNA表达分析领域具有国际领先地位。

Exiqon的销售和市场副总监Henrik M. Pfundheller认为Norgen是一家经验丰富，且拥有众多专利技术的核酸纯化试剂盒提供商，我们期待着同他们一起工作，为我们的客户提供最好的研究工具。将Norgen Biotek的产品添加到我们的miRCURY LNA产品线是一个重要的步骤，可以扩大我们的产品组合，并帮助我们实现在miRNA分析领域提供整体解决方案的目标。

Norgen Biotek公司总裁Yousef Haj-Ahmad博士介绍说：“我们很高兴看到这一协议的成功签订。Exiqon是众所周知的microRNA表达分析市场的著名公司，这一合作充分表明了我们产品的卓越质量。我们渴望与Exiqon扩大在这一领域的长期合作。

关于Norgen Biotek Corp.Norgen has a unique, proprietary platform technology with many applications, including the purification of DNA, RNA and proteins. The company holds more than a dozen issued patents, and many others are pending. Norgen has an excellent complementary portfolio of over 55 product offerings based on our technology, and among these various products we have identified at least three major areas where our products have significant competitive advantages. Our flag-ship products are:

1 - The RNA Purification Kits: Currently, we manufacture the leadingproducts for the isolation of total RNA, microRNA, cytoplasmic, andnuclear RNA from various samples including exfoliated cells found inurine.

2 - The 3-in-1 and 4-in-1 Purification Kits: We were the first company inthe world to develop kits for the purification of RNA/DNA/Proteins(3-in-1) sequentially from a single column without any sample splitting.And the 4-in-1 kit where one can sequentially isolate proteins, DNA, RNA,and microRNA using a single column, without sample splitting. Theseproducts are unique and offer a substantial cost and time savings oversample splitting and a multi-column approach. Such powerful tools are ofa significant benefit to researchers who are interested in studying thegenome, proteome and transcriptome of a single precious sample for geneexpression and biomarker discovery. Norgen is a pioneer in macromolecularfractionation and is enabling customers to study global cellular events.With the launch of these novel products Norgen earned its position as aninnovator in sample preparation.

3 - DNA, RNA & Proteins from Urine: We have developed a unique portfolioof products for the rapid purification and concentration ofinhibitor-free DNA, RNA and proteins from small volumes of urine. These products can be used for biomarker discovery, and have a good potentialto improve the sensitivity and specificity of urine-based diagnostictests.

关于Exiqon A/S。Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyse the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqons new molecular diagnostic products are based on the LNA(TM) technology that enables testing on fixed tissue. The first molecular diagnostic product was launched in December 2008. A number of new products will follow in the years ahead. Using the LNA(TM) technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.(Mat)